Navigation Links
'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
Date:10/27/2010

removed surgically. Crizotinib was resumed after the surgery, and the patient remains without evidence of disease as of September 2010, according to the investigators.

The activity of crizotinib goes beyond this rare sarcoma. The current report accompanies a paper in the same journal describing striking activity of crizotinib in a group of patients with non-small cell lung cancers (NSCLC) containing the abnormal ALK protein. Researchers from Massachusetts General Hospital, Dana-Farber/Brigham and Women's Cancer Center, and other hospitals gave crizotinib to 82 patients after standard drugs failed to halt the tumors' growth. As part of the personalized medicine effort ongoing in the Dana-Farber/Brigham and Women's Cancer Center Thoracic Oncology Program, patients with abnormal ALK were identified for the trial, underscoring the importance of tumor profiling to match drug with patient.

Results showed that 47 patients had tumor shrinkage (complete disappearance in one patient) and the cancer stopped growing in 27 patients. The ALK rearrangements are found in a small subset, about 5 percent, of patients with NSCLC, but scientists are searching for other cancers that may also be susceptible to the ALK inhibitor.

Shapiro noted that even highly successful targeted drugs like crizotinib are vulnerable to tumors' developing resistance against them. In fact, the IMT patient's tumors that developed resistance to crizotinib and were removed surgically have been studied by one of the reports co-authors, Pasi Janne, MD, PhD, also of Dana-Farber. In a paper appearing simultaneously in Cancer Research, Janne and his colleagues have identified a secondary mutation in ALK in the patient's tumor that conferred resistance to crizotinib. Furthermore, in work recently published by Janne, Shapiro and their Dana-Farber colleague, Kwok-Kin Wong, MD, PhD, the abnormal ALK proteins, including the protein with the secondary mutation that was resistant to crizotinib,
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Cook With Love This Valentines Day With Heart-Smart Recipes
2. ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones
3. Hollywood-Style Liposuction Comes to DC: Chevy Chase Smartlipo Brings Revolutionary Laser-Assisted Liposuction to DC Metro Area
4. Afternoon Nap Might Make You Smarter
5. State of Oregon Department of Human Services Selects Netsmart Technologies for Comprehensive Behavioral Healthcare Integration Project
6. SSI Announces Its Fourth Generation Revenue Cycle Management Technology, ClickON ClaimSmart Suite
7. Brain Cancer Survivor Will Cycle 4,170 Miles Across USA to Outsmart Disease
8. Conference Focuses on Aligning Two Smartest, Most Expensive Operations
9. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
10. Smart Balance to Present at Roth Growth Stock Conference
11. PA Hypnosis Center Uses 'Smart Training' Sports Psychology for Gold Medal Success
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
(Date:5/22/2015)... Pasadena, Calif. (PRWEB) May 22, 2015 ... where technology, communication and capacity are intersecting to ... and across society, the opening speaker at WesternU's ... , California Lieut. Gov. Gavin Newsom, a former ... was the keynote speaker at the graduation ceremony ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... OH (PRWEB) May 22, 2015 River ... that Kyle Johnson, the health system’s Chief Financial Officer ... interests. Johnson has served as the company CFO since ... West will be joining the health system as CFO. ... an interim basis, while the Board of Trustees conducts ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... from the Children,s Cancer Hospital at The University of Texas ... to more accurately predict treatment outcomes in young leukemia patients ... test, also known as a CBC. The results ... of Pediatric Hematology Oncology,s (ASPHO) annual meeting today. The study ...
... or friends, survey finds , FRIDAY, April 9 (HealthDay News) ... most likely to sexually abuse children when, in fact, relatives ... By doing so, parents may be failing to give their ... it happens and try to stop it, the study authors ...
... ... the issue of “medication adherence.” , ... Alexandria, VA (Vocus) April 10, 2010 -- An article in the ... the National Association of Chain Drug Stores’ (NACDS) message that pharmacy’s role in helping ...
... in the United States has experienced a conflict with ... patient care, researchers from the University of Chicago report ... Journal of General Internal Medicine . Younger and ... conflicts than their older or more religious peers. Most ...
... early recover faster, reduce sedative use, research shows , FRIDAY, ... intensive care unit may reduce their use of sedatives and ... study has found. , The amount of prescription sedatives had ... which reduced the amount of muscle weakness caused by spending ...
... ... Equals a Charitable Donation to Further the Safe Handling of Hazardous Drugs , ... COLUMBUS, OH (Vocus) April ... “Safe Handling Dance”? In recognition of National Safe Handling Awareness Month (April), Carmel Pharma, ...
Cached Medicine News:Health News:M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients 2Health News:Kids Often Misled About Child Abuse 2Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 2Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 3Health News:Primary care physicians nationwide face clinical ethical conflicts with religious hospitals 2Health News:Mild Exercise Good for the Critically Ill 2Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 2Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 3Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 4Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 5
(Date:5/22/2015)... , May 22 2015 /CNW/ - The Taskforce representing ... appreciative of all the hard work that the Minister and ... six months. This program recognizes the needs of the thalidomide ... least $75,000 a year, tax free, with annual adjustments for ... eligible for annual payments of $100,000 based on the severity ...
(Date:5/22/2015)... Solutions, Inc. (NASDAQ: BLFS ), a leading developer, manufacturer ... and cryopreservation freeze media and precision thermal ... "Company"), announced that the Company is scheduled to present at ... is scheduled to present at the Conference at 1:30 p.m. ... Hotel in New York City and ...
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... Dear President-Elect Obama:, , ... billions of dollars,earmarked for stem cell research. As spokesman ... of the Repair Stem Cell research and,treatment industry worldwide, I ... our industry and the medical and scientific professionals,hospitals, treatment centers ...
... Tenn., Nov. 24 A new cancer treatment ... weeks,of treatment, a patient,s large, stage 4 tumor ... weeks of treatment, it no longer could be ... six to nine months,after diagnosis. NeoPlas Innovation,s combination ...
Cached Medicine Technology:Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2New Cancer Treatment Shrinks Pancreatic Tumor 2
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... Utilizing technology developed over Guidants 20-year ... the new foundation for successful treatment outcomes. ... tip design with a lower profile shaft,more ... Now you can cross tight and tortuous ...
Test for AFP...
Test for AFP...
Medicine Products: